US Patent

US11925620 — Treatments with nirogacestat

Method of Use · Assigned to SpringWorks Therapeutics Inc · Expires 2043-05-19 · 17y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects improved methods of treatment using nirogacestat.

USPTO Abstract

The present disclosure relates to improved methods of treatment with nirogacestat.

Drugs covered by this patent

nirogacestat-hydrobromide (NIROGACESTAT HYDROBROMIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3754`	—	nirogacestat-hydrobromide
`U-3754`	—	nirogacestat-hydrobromide
`U-3754`	—	nirogacestat-hydrobromide

Patent Metadata

Patent number: US11925620
Jurisdiction: US
Classification: Method of Use
Expires: 2043-05-19
Drug substance claim: No
Drug product claim: No
Assignee: SpringWorks Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.